This effect is correlated with increased expression of the bone differentiation marker osteopontin, showing that BHQ880 is an anti-metastatic agent for osteosarcoma in a preclinical model [58] and is in phase 2 clinical studies for the treatment of multiple myeloma. Here, SPP1 is linked to plasma cell myeloma.